NasdaqGS:GHHealthcare
Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?
In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies.
This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...